PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 46 filers reported holding PROQR THRAPEUTICS N V in Q1 2020. The put-call ratio across all filers is 1.64 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $6,789 | -69.1% | 4,090 | -57.8% | 0.00% | – |
| Q1 2024 | $21,996 | -39.6% | 9,690 | -47.4% | 0.00% | – |
| Q4 2023 | $36,444 | +187.1% | 18,406 | +88.5% | 0.00% | – |
| Q3 2023 | $12,696 | +101.4% | 9,766 | +150.9% | 0.00% | – |
| Q2 2023 | $6,305 | -79.7% | 3,892 | -90.5% | 0.00% | – |
| Q3 2022 | $31,000 | -32.6% | 41,126 | -30.5% | 0.00% | – |
| Q2 2022 | $46,000 | +21.1% | 59,176 | +40.3% | 0.00% | – |
| Q1 2022 | $38,000 | -90.5% | 42,167 | -15.8% | 0.00% | – |
| Q4 2021 | $401,000 | +5628.6% | 50,102 | +5929.1% | 0.00% | – |
| Q3 2021 | $7,000 | -93.9% | 831 | -95.1% | 0.00% | – |
| Q2 2021 | $114,000 | +225.7% | 16,898 | +196.5% | 0.00% | – |
| Q2 2020 | $35,000 | +12.9% | 5,700 | +1.4% | 0.00% | – |
| Q1 2020 | $31,000 | -90.2% | 5,620 | -82.4% | 0.00% | -100.0% |
| Q4 2019 | $316,000 | +572.3% | 31,904 | +292.9% | 0.00% | – |
| Q3 2019 | $47,000 | – | 8,120 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Copernicus Capital Management, LLC | 40,000 | $335,000 | 4.05% |
| Opaleye Management Inc. | 1,424,200 | $11,921,000 | 2.23% |
| Prosight Management, LP | 282,256 | $2,362,000 | 1.30% |
| RTW INVESTMENTS, LP | 6,443,113 | $53,929,000 | 0.81% |
| DAFNA Capital Management LLC | 296,383 | $2,481,000 | 0.66% |
| Kerrisdale Advisers, LLC | 453,182 | $3,793,000 | 0.41% |
| Altium Capital Management LP | 125,000 | $1,046,000 | 0.27% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,079,668 | $17,407,000 | 0.21% |
| Alpha Paradigm Partners, LLC | 44,323 | $371,000,000 | 0.15% |
| GSA CAPITAL PARTNERS LLP | 137,003 | $1,147,000 | 0.12% |